Acknowledgements: we thank John Slater for his comments on an earlier version of this paper. Laurel Edmunds is supported by the NIHR Oxford BRC Innovation is an integral part of economic development in developed economies. In the post 2008 period, a key policy agenda is that of sustainable development, which calls for innovation in all aspects of value-chains. In this paper, we focus on innovation from the biotech -pharma perspective to see whether or not this will lead to a sustainable future for the regions where there are clusters of firms in this sector. We examine data from a recently completed European Union study of innovation in the Healthcare sector from the UK and Switzerland, countries with an historical base in pharma, to understand how innovation pathways vary at the regional level in the broader life sciences, which incorporate biotech and more. Innovation in the healthcare sector in two regions, Oxfordshire in the UK and Zurich in Switzerland are compared. We contextualize our discussion by drawing on studies that focus on the sector in the United States, specifically Boston. The analytical framework comprises three elements: innovation systems and national and regional economic development theories are the first two, followed by approaches which consider organizational or institutional activity. This framework is used to help explain and understand the complexity of how innovation is organized at the sub-national level. The overall context is that it is increasing becoming a condition for government financing of research that it has more immediate application in industry or have the possibility of commercialisation (e.g., translational research).
Introduction
Although innovation is an integral part of economic development in the developed economies of Western Europe and the United States, competitive pressures are now felt from all around the world, especially the East Asian nations, Brazil, India, and Russia. Both the US and the UK went through industrial restructuring in the 1980s, IT revolution in the 1990s, and the biotech craze in the 2000s. In the post 2008 economic downturn, the focus is on sustainable development, which calls for further innovation in all aspects of value-chains. In this paper, we focus on innovation capacity at the regional level from the life sciences sector, which incorporates the biotech/healthcare sector (broadly defined). The goal is to use a series of innovation indicators in specific regions in order to explore cross-national diversity identifying where regions are stronger and weaker in their capacities for sustaining innovation and competitiveness. These indicators include institutional factors, political, legal and cultural; as well as specific advantages for entrepreneurial activities of public research institutes in the case of the biotech/healthcare sector.
Here the indicators are used to examine innovation capacity in Oxfordshire in the UK and Zurich in Switzerland -both locations are places which have strong historical bases in the biomedical research. From this evidence, we argue that not all countries or regions will converge in terms of future innovation paths and outcomes. We contextualize our discussion by drawing on studies that focus on the sector in the United States, specifically Boston, which is one of the three places in the US that are at the forefront of innovation in bio-pharma (Breznitz and Anderson 2006) . Boston is far in advance of either Oxfordshire or Zurich.
Several theories inform the interpretation of the data. The analytical framework comprises three elements: innovation systems and national and regional economic development theories are the first two, followed by approaches which consider organizational or institutional activity. A key theoretical theme is that of historical anchor organizations (Feldman 2003) . Anchors in this context include major research and industrial organizations, such as universities, hospitals, and big pharmaceutical companies. Their prominence in certain locations relates to the prestige of top universities and their ability to attract the best people as well as research income from public, private and charitable bodies. In the case of the big pharma, factors relating to the reasons why they were established in certain places and why they stay there (national and local factors) are considered. Conceptually, the paper explores how the development of regional specializations in the healthcare sector is associated with historical anchors and how and why they might be linked to sustainable innovation pathways in the future.
This framework is used to help explain and understand the complexity of innovation processes, that is, convergence and divergence in innovation capacity. The overall context is an increasingly made a condition for government finance of research of having more immediate application in industry or possibilities of commercialization (e.g. translational research).
The data are drawn from a recently completed five country European project, HealthTIES (2010 HealthTIES ( -2013 1 , the objective of which was to identify how regions differ in their strengths and weaknesses in order to inform policy. Four regions were chosen on the basis that that they are four of the top bioscience & technology regions in Europe and combine clinical science with engineering science, businesses, regional authorities, and well-established Bioscience Parks (the others being Leiden-Delft, Netherlands, and Biocat in Spain). The fifth was a developing region in Hungary.
The two regions here were chosen to illustrate the value of the methodology in two places with some similar attributes, and to show how innovations arise from geographic specificities of local investors, major research universities, existing companies and highly skilled labor markets.
We show that Zurich performs better on most indicators than Oxfordshire, having elements of both early and late stage biotech and pharmaceutical sector activity.
However, a limitation of all of these kinds of study is that they are not able to demonstrate the effects of location with regard to the broader geographical context.
For example, Oxfordshire is only one part of the Golden Triangle of Oxford, Cambridge and London universities which collectively have large scale research strengths. Zurich is a major centre of the country's biopharma industry and is not far away from Basel where the headquarters of three of the world's largest companies are located and might be seen as being in competition for resources and firms. We therefore argue that both cases highlight the complexity of speculating on future local growth trajectories in a particular sector in isolation from its broader geography.
Explaining the development of innovation capacity
Three geographic scales, the country, the region (locality) and the organization, are considered to understand where spillovers in the form of symbiotic relationships between local firms and other organizations (Agarwal et al. 2007) Asheim et al. 2006 ).
In the mid 20 th century, the role of government emerged as Keynesian views received broader acceptance. This has continued with many ups and downs. Science and technology policy at various scales have created anchor institutions that lead to possibilities for innovation at the local level with far reaching impacts for collaboration and human development (e.g., National Institutes of Health (NIH) in the United States).
National innovation systems' (Freeman 1995 , Lundvall 1988 & 1992 , Nelson 1988 and 1993) analysis of inputs and outputs into an innovation system includes industries and firms (the central elements of the system) but also actors and organizations including the research base in science and technology as well as innovation/technology policy (Carlsson et al. 1999) . The national innovation system essentially consists of three sectors: industry, universities, and the government, with each sector interacting with the other, while at the same time having an independent existence (Goto 2000) -the Triple Helix model describes these relationships in greater detail (Etzkowitz and Leydesdorff 1995) .
Within national contexts, we can trace such institutions from the Fordist era, the information technology revolution, the biotech revolution to the current life sciences focus with a goal toward sustaining and improving health and human development.
However, the specific difference between life sciences and other clusters is the specific requirements relating to the capital infrastructure, including lab facilities (e.g., wet labs), health and safety regulations, people with formal scientific qualifications and the realization that many innovations come directly out of university labs to patients/hospitals. Typically, a biological agent is discovered in a university lab and is patented. Then, a licensing agreement with a company is reached for commercialization (Breznitz and Anderson 2006 National R&D spending is often attributed to cross-country differences in innovation and high technology productivity (Fagerberg et al. 2014 Indicators at national level seem to be important for small European countries.
However, almost every country has a particular city or a region that has captured the value chain activities (from research to production), which is indicative of agglomeration economies or historic development of anchor institutions, policy, related infrastructures, and labour markets. Some dispersal is present, but the recent phenomenon of intense clustering cannot be ignored in places such as Zurich and
Oxford. In each, as we will show later, they are underpinned by healthcare infrastructure, research systems and to varying extent the commercial components of the sectoral innovation system (big pharma, subsidiaries and biotech firms). In turn these regional characteristics define the localities' positions within national (and international) systems of innovation.
The regional level
In recent literature on high technology and biopharma, the focus has been on understanding what differentiates the high performing regions from the periphery or ordinary regions. The evolutionary economic geography literature discusses regional pathways (see for example Boschma and Frenken 2011) . In this context, these pathways in translational research point to outputs that indicate what the innovation chain looks like in the broader healthcare sector, that is, the directions it is taking and the specialisations in research. They also raise the question of why some are more effective than others in translating into commercial products. Big pharma and its subsidiaries, biotech firms, universities of which parts of the innovation system are present in each region, are significant in determining pathways -or indicate how regions are differentiated in terms of resources, networks, outputs and so on. to be key in the creation of networks which build capacity and sustain regional economic development (Feldman 2014 ).
The regional systems of innovation (RIS) concept (Cooke et al. 1992 (Cooke et al. , 1998 (scientific publishing), university R&D expenditures, government R&D expenditures and tertiary education, the US led except in the area of university R&D, whereas government R&D was much higher. Overall, the knowledge infrastructure benefitted high-tech regions in the US disproportionately. However, Fagerberg et al. (2014) concluded that most European countries, particularly the top performers, are just as
The organizational level
The effects of anchor institutions including firms and universities in local development have been found to be stronger when they are located in close proximity with enterprising firms and other stakeholders such as firms providing professional services and local public policy organizations. The theory of the Anchor Firm originally applied to the development of shopping malls. Since then it has been applied to a both low and high tech sectors shopping malls (Konishi and Sandfort, 2003) , R&D intensive firms (Agrawal & Cockburn, 2003) , the aircraft industry (Niosi and Zhegu, 2010) and the biotech industry (Feldman, 2003) . Existing firms can serve as anchors that attract skilled labor pools, specialized intermediate industries and
provide knowledge spillovers that benefit new technology intensive firms in the region. This can positively affect firm survival and growth and subsequently the viability of the regional clusters (Feldman, 2003) .
The presence of large global firms within a local economy under some circumstances can act as catalysts for innovation, labor force development and trade (Spencer 2013 , see also Markusen 1996 ). An anchor, in the form of a large, established firm therefore may create externalities that benefit agglomerations. These can create local advantages such as pools of skilled labor and demand for specialized products, which may benefit smaller start-up firms (Feldman, 2003) . They can produce positive agglomeration effects on a region by spinning off new local innovative firms and by attracting other innovative firms to the region (Niosi and Zhegu, 2010) . FRIDA (2014) also concluded that anchor firms and the networks they create constitute 'key drivers' of the European Union's 2020 growth strategy. The anchor firms have the capacity to upgrade local economies and thereby contribute to a more dynamic economy in Europe overall. Feldman (2003) considered the locational dynamics of the US biotech industry in relation to the anchor firm hypothesis. For the US biotech industry, the geographic location of the industry appears to be anchored by some large institutions, related firms and successful early entrants to the industry. More generally, regional anchors may encompass other institutions such as universities, government labs, research institutes and other entities (Feldman, 2003) . What is important is the extent to which they work with other parts of the value chain to enable their locations to function as places of high efficiency in the creation, transfer and application of knowledge (Breznitz and Anderson 2006) .
More recently, Spencer (2013) set out to test whether proximity delivers superior advantages for smaller businesses and entrepreneurial activity in four sectors in Canada, including bio-pharma. This sector in Canada, as in the US, is mainly clustered in large urban areas, with educated populations and top-rate research institutions, and relies less on material inputs and more on knowledge for competitiveness. He found, however, that there was not enough strong evidence to suggest that close proximity to anchor firms made a significant difference to firm performance. This finding is relevant to the regions in this study.
This finding provides further justification for study of how the presence of a university as an anchor institution in a locality affects the behavior of its academics and the potential for fostering network activities in the broader healthcare sector, which includes bio-pharma. While this implies that such networks occur spontaneously, often the process of making networks requires facilitation. A facilitating process can include academic engagement -which represents an important way by which academic knowledge is transferred -or translated -into the industrial domain (Perkmann et al. 2014) . These authors that show the forms that it takes is related to the characteristics of individuals as well as the organizational and institutional contexts in which they work. The motives and outcomes for university and industry interactions in the UK are also examined by Ankrah et al. (2013) . They found a match of motives and beneficial outcomes for university and industry actors, in spite of differing work environments. Thus government funding for collaboration was justified by the benefits to individual organisations (rather than societal benefits).
However, organizational behavior and academic links with industry vary by academic experience and by place (Jong 2008 , 2012 & Jong and Slavova 2014 . Jong (2008) finds differences in the behavior of therapeutic biotech firms in Cambridge and The section below presents the description of the data used to compare the two example regions: Oxfordshire and Zurich. First, the data source is described. Second, each of the two regions are characterized based on a discussion of their national and regional system of innovation as well as specific local characteristics. Third, regional comparisons of inputs, innovation system/structure, and outputs are presented for the broader life sciences. Fourth, these two regions are set against one of the leaders in bio-pharma innovation -Boston. A discussion of the regional characteristics of
Boston is followed by a comparison of the three regions across several areas of specialization in life sciences to show possibilities for collaboration or lack thereof.
Methodology, Data, and Findings

Methodology and Data
One of the key problems in comparing regions is the availability of comparable data as reliable indicators of a particular phenomenon. In this study, the Innovation (Tables 1-3 ) and h-indices for diseases and technology platforms (Table 4) .
Regional Contexts
Oxfordshire/UK
Oxfordshire's population is approximately 2.7 million. It is the leading component of for medical technologies (OMT). This formerly local company, is still to some extent an anchor firm (Feldman 2003) , being a world centre for design and R&D in magnet technology.
The Life Science group accounts for 56% of all companies. The Medical Technology group accounts for the remaining 44%. Looking at the evolution of these two groups over time in terms of company formation, it is also noteworthy that the Life Science group, initially the largest one, has become progressively less dominant. This also indicates how the characteristics or attributes of the system are changing (Carlsson et al. 1999) . However, the industry mix does not include either the research or production activities of big pharma anchor firms -which are represented to a greater extent in Cambridgeshire. For example in 2013, AstraZeneca announced the move of its headquarters from London to Cambridge 9 .
In spite of the strong focus on R&D, the region lacks capabilities in commercialization as indicated by the much smaller number of biotech companies than in Zurich. This shows that the basic conditions in Oxfordshire are very different from Zurich. While Oxford University dominates and its translational trajectory is predicated on its very strong science base, the institutional support system is limited.
Moreover, the lack of large R&D intensive firms in the life sciences sector is particularly distinctive of how the overall biomedical sectoral system of innovation (Malerba 2002) 
Zurich/Switzerland
Switzerland is the most competitive business location in the world according to the There are some 4800 healthcare companies in the Canton. In addition, most universities have their own internal incubation programs, allowing young companies to develop business ideas whilst using the scientific infrastructure in the initial stages and finally to profit from supportive technology transfer circumstances. Life sciences, especially the pharmaceutical industry in Switzerland, play an important role in this development. LSZ is a virtual region with a small physical co-ordination base.
It was established in 2001 by University of Zurich and the Federal Institute of
Technology Zurich (ETHZ). It aims to establish co-operation networks bringing together academia, industry and the public sector, and support science education.
Approximately 80 % of the cluster activities are related to human health. It is the headquarters of the anchor firm Pfizer AG and is the location of the Roche Innovation Center Zurich, which has a multinational team of some 140 employees -95% of whom are research scientists 13 .
Comparative Inputs, Infrastructure, and Outputs in Oxfordshire and Zurich
Generally the data show a snapshots of each location at 2010, or periods leading up to 2010. Without repeated measures, we cannot infer how stable, typical on average, or dynamic any of the regions are for any of the indicators, but the results are directly comparable, detailed and objective. Knowledge and research funding patterns (see Table 1 ) show that for professors with an h-index equal to or greater than 30, the Oxford (238) and Zurich (231) Table 1 here
With respect to human capital in the life sciences, Zurich exceeds the total number for Oxford in graduate students, particularly for international students. This may just reflect the capacity of support in Zurich. Moreover, in terms of senior ERC grants, Zurich is a long way ahead of Oxford while the amount of grants for junior scientists is comparable. This shows that early career support is competitive in Oxford. This demonstrates a difference in spillover capacity in relation to the quantity (supply) and characteristics of the skill base (Agrawal et al. 2007 , Spencer 2013 , Feldman 2014 ) in the two locations.
In terms of healthcare infrastructure, the data show that Oxford has the lead in clinical trials, but the areas available for research in universities and research beds in hospitals are larger in Zurich, whereas Oxford has a more general facility. Indictors of innovation systems, patents, spinoffs, private projects and TTO are shown in Table 2 .
The overall science park space and personnel support is greater in Oxford, reflecting the presence of the Oxford Science Park in Oxford, Oxford University's own science park at Begbroke and two major sites to the south of the county at Milton Park Table 2 here Consistent with the input data in Table 1 , the picture on output shows that Oxford is ahead at the exploration phase while Zurich is ahead in the exploitation phase (see Table 3 ). Zurich has more biotech companies and products on the market while Oxford leads in clinical trials, discovery phase products, investments especially series A investments etc. Oxford fits our understanding (see Cooke 2001 ) of a place/institution with early phase focus while Zurich fits the late phase focus. Zurich has the advantage of having the knowledge to take products to market and it is not far behind in discovery phase numbers, patents etc. Zurich has better opportunities for benefitting from more industrial engagement leading to innovation within its system. (Dicken, 2015) .
Comparison with US/Boston/Massachusetts
By way of contrast, we consider the scale and scope of activities in Boston which is the world's leading biotech cluster, one which is tightly clustered (Breznitz and Anderson 2006) , and has a mix of types of firms. It is also one that has strong anchors (universities and big firms), attracts major amounts of money from public and private sector organisations, has a very highly skilled labour force, and has developed a very strong infrastructural support system. The mix of firms is important (Malerba 2002) . There are a growing number of manufacturing assets in Massachusetts because of a workforce highly skilled in biologics process development. In addition to a number of contract manufacturers, Massachusetts is also home to commercial manufacturing for Genzyme, Biogen-Idec, AbbVie, Shire, and Pfizer. This makes it different to other bio-pharma clusters in North America (Spencer 2013) because it includes material inputs and outputs.
Hence, as more of the innovation value chain is located in state, the potential for a greater range of spillovers is increased (Agarwal et al. 2007 ). Breznitz and Anderson (2006) in a survey of why biotech firms cluster in the Cambridge Massachusetts area found that the pool of skilled labor was the most important factor, followed by access to university labs (many of the founders came from university labs). The former is linked to the universities which supply qualified people. Access to hospitals was much lower. However, as in other surveys e.g. Mckelvey et al. (2003) found that in Sweden, firms did not rate access to other firms 
Conclusions
This study considers two exemplar regions Oxfordshire and Zurich to illustrate similarities and differences in inputs, infrastructure and outputs. These depict innovation capacity in the broader life sciences which includes academics, industry, as well healthcare and/or clinical facilities. In addition, the study contrasts these two regions with one of the leaders in this broad sector, Boston/Cambridge Massachusetts.
It has taken three geographical scales -national, regional and organizational -to reflect on what makes them unique and therefore how they differ in their development to others with some similarities in research and industry characteristics.
The results show each location's position as leaders in their national as well as international systems of innovation. Oxford excels in terms of inputs (e.g., science base). In particular, at the organizational level, Oxford has academic excellence as indicated by the very high level of publications in leading journals. This in part is related to the necessity of Oxford University's academics maintaining its leading world rankings thus enabling it to attract the best staff and students as well as research income.
However, at the regional level, Oxford's performance as a diffuser of innovation through the formation and growth of spin-off firms (Agrawal et al. 2007 ) appears to be focused on generating startups/small companies that are later bought out by bigger players thus removing the potential for the growth of anchor firms (Feldman 2003 , Spencer 2013 . Oxford University does not appear to be an anchor institution other than in research (see Autant-Bernard et al. 2006) , and therefore is not as a leader of innovation, and its contribution to regional innovation capacity is limited except in specific respects. Here Oxford is similar to Boston as it follows the same pattern of focus on cardiovascular disease, cancer and clinical trials but to a lesser extent.
Moreover, there is a smaller pool of graduates in the healthcare disciplines than in Zurich which also limits feed into translational research.
However, parts of an innovation support system are in place -such as the space on science and business parks, while the lack of a bioincubator is being addressed.
However, some of the more structural problems include an absence of R&D intensive big pharma anchor firms (Agrawal and Cockburn 2003) and the kind of public sector support which is needed for a RIS (Cooke 1992 , Asheim and Coenen 2005 which is present in Massachusetts.
Zurich and Switzerland which has a generally healthier population, appears to have better funding than Oxford generally and possibly its academics have less pressure to publish in top journals. Zurich appears to have greater innovation capacity being better at growing companies than Oxfordshire and also benefits from of the presence of big pharma (see Feldman 2003 , Spencer 2013 . With respect to diffusion of innovation (Agrawal et al. 2007) , Zurich is similar to Boston as it appears to invest comparatively more in technologies.
There is evidence here, therefore, to support Jong (2008) and Jong and Slavova (2014) that organizational behavior and academics' links with industry vary by academic experience and by place. In Oxfordshire and Zurich, this is also related to varying levels of research funding and supply of graduates. This is reflected in Oxfordshire's position in the national sectoral system of innovation (Malerba 2002 (Malerba , 2005 as being at the exploration stage compared to Zurich's greater capacity for innovation at the exploitation stage. That said, both regions have the base to become bigger and better in discovery, therapeutics, diagnostics, clinical research etc.
However, this does not make generalizations with respect to policy easy. Each region follows its own pathway in which individuals make their own choices about collaboration in the light of funding opportunities. Therefore in this complex industry, specific policies necessarily relate to what each cluster has done so far and what it could do in the future based on current assets.
Moreover, it is difficult to quantify micro-geographies, that is, the location of departments within a campus, the culture of collaboration in universities, the tradition and practice of reaching out to scientists in institutes and industry for furthering translational research, and finally, the tolerance of funding agencies to lag times and failures. While a field trip to Stanford, Berkeley, and MIT would show how various types of proximity can work, in other places, this is not as apparent. This lack of transparency may be the "unquantifiable" that cannot be captured and operationalized by one agent (e.g., policymaker) or by one firm.
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